Analysts’ Weekly Ratings Changes for Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (NASDAQ: SRPT) recently received a number of ratings updates from brokerages and research firms:

• 7/28/2026 – Sarepta Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 7/20/2026 – Sarepta Therapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 7/9/2026 – Sarepta Therapeutics had its price target lowered by Piper Sandler from $23.00 to $20.00. They now have a “neutral” rating on the stock.
• 7/9/2026 – Sarepta Therapeutics was upgraded by Wolfe Research from “peer perform” to “outperform”. They now have a $27.00 price target on the stock.
• 7/7/2026 – Sarepta Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/4/2026 – Sarepta Therapeutics was upgraded by Wall Street Zen from “hold” to “buy”.
• 6/29/2026 – Sarepta Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 6/11/2026 – Sarepta Therapeutics was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.